Literature DB >> 19002912

Assessment of the number of local cytotoxic T lymphocytes required for degradation of micrometer-size tumor spheroids.

K Kawai1, H Hayashi, Y Ozaki, K Saijo, S Q Liu, H Akaza, T Ohno.   

Abstract

Adoptive immunotherapy with human cytotoxic T lymphocytes (CTL) is a promising cancer treatment. Previously we showed that human CTLs against various types of tumors can be efficiently produced by coculturing peripheral blood cells with target cells. The aims of this study were to simulate the interaction of CTLs and micrometer-size tumor tissues in vitro and to assess the required number of CTLs at local tumor sites for degradation of a tumor. Allogeneic CTLs against a human transitional cell carcinoma cell line and autologous CTLs against a renal cell carcinoma cell derived from a surgical specimen were generated. The cytotoxic activities of CTLs against tumor cells in monolayer culture and tumor spheroids formed in U-bottom 96-well culture plates were assessed. Both allogeneic and autologous CTLs showed greater destructive activity than lymphokine activated killer (LAK) cells against target tumor spheroids. CTLs inoculated at E/T ratios of 0.1 to 1 coexisted with the tumor spheroid for 5 to 6 days and then increased in number with apparently lethal activity against the tumor spheroid. In contrast to CTLs, the increase in LAK cell numbers was scarcely observed, and the proliferated LAK cells did not show cytotoxicity against the tumor spheroid. These observations suggest that, when a small number of CTLs reach a local tumor site, they can destroy micrometer-size tumors after considerable local proliferation.

Entities:  

Year:  2001        PMID: 19002912      PMCID: PMC3449972          DOI: 10.1023/A:1016139010531

Source DB:  PubMed          Journal:  Cytotechnology        ISSN: 0920-9069            Impact factor:   2.058


  20 in total

1.  Formation of multicellular spheroids composed of adult rat hepatocytes in dishes with positively charged surfaces and under other nonadherent environments.

Authors:  N Koide; K Sakaguchi; Y Koide; K Asano; M Kawaguchi; H Matsushima; T Takenami; T Shinji; M Mori; T Tsuji
Journal:  Exp Cell Res       Date:  1990-02       Impact factor: 3.905

2.  Effect of LAK cells against three-dimensional tumor tissue. In vitro study using multi-cellular human glioma spheroids as targets.

Authors:  J Jääskeläinen; P Kalliomäki; A Paetau; T Timonen
Journal:  J Immunol       Date:  1989-02-01       Impact factor: 5.422

3.  Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2.

Authors:  A E Chang; A Aruga; M J Cameron; V K Sondak; D P Normolle; B A Fox; S Shu
Journal:  J Clin Oncol       Date:  1997-02       Impact factor: 44.544

4.  Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report.

Authors:  S A Rosenberg; B S Packard; P M Aebersold; D Solomon; S L Topalian; S T Toy; P Simon; M T Lotze; J C Yang; C A Seipp
Journal:  N Engl J Med       Date:  1988-12-22       Impact factor: 91.245

5.  Characteristics and in vivo homing of long-term T-cell lines and clones derived from tumor-draining lymph nodes.

Authors:  T Matsumura; J J Sussman; R A Krinock; A E Chang; S Shu
Journal:  Cancer Res       Date:  1994-05-15       Impact factor: 12.701

6.  Clinical results and characterization of tumor-infiltrating lymphocytes with or without recombinant interleukin 2 in human metastatic renal cell carcinoma.

Authors:  R M Bukowski; W Sharfman; S Murthy; P Rayman; R Tubbs; J Alexander; G T Budd; J S Sergi; L Bauer; V Gibson
Journal:  Cancer Res       Date:  1991-08-15       Impact factor: 12.701

7.  Systemic T cell adoptive immunotherapy of malignant gliomas.

Authors:  G E Plautz; G H Barnett; D W Miller; B H Cohen; R A Prayson; J C Krauss; M Luciano; D B Kangisser; S Shu
Journal:  J Neurosurg       Date:  1998-07       Impact factor: 5.115

8.  Clinical application of retroviral gene transfer in oncology: results of a French study with tumor-infiltrating lymphocytes transduced with the gene of resistance to neomycin.

Authors:  Y Merrouche; S Negrier; C Bain; V Combaret; A Mercatello; B Coronel; J F Moskovtchenko; P Tolstoshev; R Moen; T Philip
Journal:  J Clin Oncol       Date:  1995-02       Impact factor: 44.544

9.  Additive effects of antitumor drugs and lymphokine-activated killer cell cytotoxic activity in tumor cell killing determined by lactate-dehydrogenase-release assay.

Authors:  K Kawai; T Sasaki; K Saijo-Kurita; H Akaza; K Koiso; T Ohno
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

10.  In vivo trafficking of adoptively transferred interleukin-2 expanded tumor-infiltrating lymphocytes and peripheral blood lymphocytes. Results of a double gene marking trial.

Authors:  J S Economou; A S Belldegrun; J Glaspy; E M Toloza; R Figlin; J Hobbs; N Meldon; R Kaboo; C L Tso; A Miller; R Lau; W McBride; R C Moen
Journal:  J Clin Invest       Date:  1996-01-15       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.